Topical Treatment of Cutaneous Lesions of Acquired Immunodeficiency Syndrome–Related Kaposi Sarcoma Using Alitretinoin Gel

Duvic, Madeleine; Friedman‐Kien, Alvin E.; Looney, David J.; Miles, Steven A.; Myskowski, Patricia L.; Scadden, David T.; Roenn, Jamie Von; Galpin, Jeffrey E.; Groopman, Jerome E.; Loewen, Gordon; Stevens, Victor J.; Truglia, J. A.; Yocum, Richard C.

doi:10.1001/archderm.136.12.1461

Cited by 73 publications

(39 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…data]. Alitretinoin gel is approved for the topical treatment of Kaposi’s sarcoma lesions [43]. These two responses prompted us to prospectively investigate the activity of bexarotene in additional patients with LyP or LyP plus mycosis fungoides.…”

Section: Discussionmentioning

confidence: 99%

Bexarotene Is a New Treatment Option for Lymphomatoid Papulosis

Krathen

Ward

Duvic³

2003

Dermatology

Self Cite

View full text Add to dashboard Cite

Background: Lymphomatoid papulosis (LyP) is a clonal T cell proliferation with large cell histology, a chronic course, and an increased risk of lymphoma. Bexarotene (Targretin^®) is an RXR-selective retinoid (rexinoid) approved for the cutaneous manifestations of cutaneous T cell lymphoma. Objective: To determine whether bexarotene is effective in treating LyP. Methods: Ten patients with chronic and symptomatic LyP were prospectively treated with oral (n = 3) or topical gel (n = 7) formulations of bexarotene. Results: A favorable response to bexarotene treatment with decreased numbers or duration of lesions was seen in all with objective responses in 8 patients. Conclusions: Bexarotene may be an effective palliative treatment for LyP, warranting further controlled studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Bexarotene Is a New Treatment Option for Lymphomatoid Papulosis

Krathen

Ward

Duvic³

2003

Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has been approved since 1999 for the treatment of Kaposi sarcoma, but has not been evaluated in any complete study for the treatment of MF. [82][83][84] In the 1990s, 2 phase I/II trials were performed to evaluate the effect of topical bexarotene and topical alitretinoin in MF. The study found that 7 patients had some response to topical alitretinoin 0.1% gel with twice-daily applications.…”

Section: Alitretinoinmentioning

confidence: 99%

“…84 Adverse cutaneous reactions of all the topical retinoids are similar, with the most frequent symptoms being local dryness, burning, erythema, and desquamation. 75,76,[82][83][84] Vesiculobullous eruptions have also occurred with topical bexarotene use. 85 Rarely, allergic contact dermatitis occurs with topical retinoids.…”

Section: Alitretinoinmentioning

confidence: 99%

See 1 more Smart Citation

Skin-Directed Therapies in Cutaneous T-Cell Lymphoma

Nguyen

Bohjanen

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Early stage mycosis fungoides represents the most common clinical presentation of cutaneous lymphoma, with skin-directed therapies long established in its treatment. These therapies continue to change as new treatment regimens emerge. Other skin-directed treatments include light and radiation therapy. Therapies with higher levels of evidence and less systemic toxicity are usually preferred as first-line treatment. However, even these established therapies, like topical corticosteroids and carmustine, lack randomized clinical trials to establish their efficacy. Research is also needed to further define the role of combination topical therapies and how skin-directed therapies can be used as adjuvants to systemic medications.

show abstract

“…Factors that appear to influence which effect is observed include the specific retinoid utilized, when infection is initiated relative to exposure to the retinoid, and whether the cells have been exposed to another activating stimulus [39,40, 45,44,47] . In clinical studies involving patients with HIV infection, 13-cis retinoic acid induced regression of oral leukoplakia [48], and AIDS-related Kaposi's sarcoma lesions have been shown resolve with treatment with topical preparations of either 9-cis RA or the synthetic RXR-specific retinoid agonist bexarotene [49,50].…”

Section: Retinoids and Hiv Infectionmentioning

confidence: 99%

Retinoids and Opioids: Factors in the Development of HIV-Related Neurological Disease

Royal¹,

Bryant²

2008

American J. of Infectious Diseases

View full text Add to dashboard Cite

Neurological disease occurs frequently in HIV-infected individuals and may occur at even higher rates among infected drug users. Among the potential mechanisms that promote such impairment, retinoid deficiency may have selective effects that could both lead to alterations in immune function and enhanced replication of HIV. Studies are currently underway to examine the possible selective effects of retinoid receptor activation and interactions with opioids on the pathogenesis of neurological disease in the transgenic rat model of HIV infection.

show abstract

Topical Treatment of Cutaneous Lesions of Acquired Immunodeficiency Syndrome–Related Kaposi Sarcoma Using Alitretinoin Gel

Cited by 73 publications

References 25 publications

Bexarotene Is a New Treatment Option for Lymphomatoid Papulosis

Bexarotene Is a New Treatment Option for Lymphomatoid Papulosis

Skin-Directed Therapies in Cutaneous T-Cell Lymphoma

Retinoids and Opioids: Factors in the Development of HIV-Related Neurological Disease

Contact Info

Product

Resources

About